Fas polymorphisms influence susceptibility to autoimmune hepatitis

American Journal of Gastroenterology

Volumn 100, Issue 6, 2005, Pages 1322-1329

  Hiraide, Akira ^a   Imazeki, Fumio ^a   Yokosuka, Osamu ^a   Kanda, Tatsuo ^a   Kojima, Hiroshige ^a   Fukai, Kenichi ^a   Suzuki, Yoichi ^a   Hata, Akira ^a   Saisho, Hiromitsu ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; CONTROLLED STUDY; DNA POLYMORPHISM; FAS GENE; FEMALE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; HUMAN TISSUE; HYPOTHESIS; JAPAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIGENS, CD95; BIOPSY; DNA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HEPATITIS, AUTOIMMUNE; HUMANS; LINKAGE DISEQUILIBRIUM; LIVER; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES;

EID: 21344432363     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41053.x     Document Type: Article

References (48)

1. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
2. Manns MP, Strassburg CP. Autoimmune hepatitis: Clinical challenges. Gastroenterology 2001;120:1502-17.
3. Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112:2028-35.
4. Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25:317-23.
5. Seki T, Kiyosawa K, Inoko H, et al. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990;12:1300-4.
6. Doherty D. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994;19:609-15.
7. Czaja AJ, Cookson S, Constantini PK, et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999;117:645-52.
8. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999;30:851-6.
9. Doherty DG, Underbill JA, Donaldson PT, et al. Polymorphism in the human complement C4 genes and genetic susceptibility to autoimmune hepatitis. Autoimmunity 1994;18:243-9.
10. Agarwal K, Czaja AJ, Jones DE, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31:49-53.
11. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002;35:126-31.
12. Neuberger J. Primary biliary cirrhosis. Lancet 1997;350:875-9.
13. Manns MP, Bremm A, Schneider PM, et al. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991;101:1367-73.
14. Gores GJ, Moore SB, Fisher LD, et al. Primary biliary cirrhosis: Associations with class II major histocompatibility complex antigens. Hepatology 1987;7:889-92.
15. Underhill J, Donaldson P, Bray G, et al. Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype. Hepatology 1992;16:1404-8.
16. Gregory WL, Mehal W, Dunn AN, et al. Primary biliary cirrhosis: Contribution of HLA class II allele DR8. Q J Med 1993;86:393-9.
17. Briggs DC, Donaldson PT, Hayes P, et al. A major histocompatibility complex class III allotype (C4B 2) associated with primary biliary cirrhosis (PBC). Tissue Antigens 1987;29:141-5.
18. Mehal WZ, Gregory WL, Lo YM, et al. Defining the immunogenetic susceptibility to primary biliary cirrhosis. Hepatology 1994;20:1213-9.
19. Oguri H, Oba S, Ogino H, et al. Susceptibility to primary biliary cirrhosis is associated with human leukocyte antigen DRB1 *0803 in Japanese patients. Int Hepatol Commun 1994;2:263-70.
20. Mukai T, Kimura A, Ishibashi H, et al. Association of HLA-DRB1*0803 and *1602 with the susceptibility to primary biliary cirrhosis. Int Hepatol Commun 1995;3:207-12.
21. Agarwal K, Jones DE, Daly AK, et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000;32:538-41.
22. Donaldson P, Agarwal K, Craggs A, et al. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: Associations with disease progression and disease susceptibility. Gut 2001;48:397-402.
23. Kanemitsu S, Ihara K, Saifddin A, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002;29:1183-8.
24. Horiuchi T, Nishizaka H, Yasunaga S, et al. Association of Fas/APO-1 gene polymorphism with systemic lupus erythematosus in Japanese. Rheumatology (Oxford) 1999;38:516-20.
25. Bolstad AI, Wargelius A, Nakken B, et al. Fas and Fas Hg- and gene polymorphisms in primary Sjogren's syndrome. J Rheumatol 2000;27:2397-405.
26. Huang QR, Teutsch SM, Buhler MM, et al. Evaluation of the apo-1/Fas promoter mva I polymorphism in multiple sclerosis. Mult Scler 2000;6:14-8.
27. Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol 1994;24:3057-62.
28. Cheng J, Liu C, Koopman WJ, et al. Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 1995;154:1239-45.
29. Inazawa J, Itoh N, Abe T, et al. Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 1992;14:821-2.
30. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
31. Rudert F, Visser E, Forbes L, et al. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. DNA Cell Biol 1995;14:931-7.
32. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.
33. Niino M, Kikuchi S, Fukazawa T, et al. An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis. BMC Neurol 2002;2:8.
34. Scully LJ, Toze C, Sengar DP, et al. Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology 1993;104:1478-84.
35. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000;174:250-9.
36. Bittencourt PL, Goldberg AC, Cancado EL, et al. Different HLA profiles confer susceptibility to autoimmune hepatitis type 1 and 2. Am J Gastroenterol 1998;93:1394-5.
37. Strettell MD, Thomson LJ, Donaldson PT, et al. HLA-C genes and susceptibility to type 1 autoimmune hepatitis. Hepatology 1997;26:1023-6.
38. Tanaka A, Quaranta S, Mattalia A, et al. The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J Hepatol 1999;30:826-9.
39. Jones DE, Watt FE, Grove J, et al. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol 1999;30:232-6.
40. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-29.
41. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
42. Kondo T, Suda T, Fukuyama H, et al. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997;3:409-13.
43. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000;108:567-74.
44. Siegel RM, Fleisher TA. The role of Fas and related death receptors in autoimmune and other disease states. J Allergy Clin Immunol 1999;103:729-38.
45. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-51.
46. Briggs MR, Kadonaga JT, Bell SP, et al. Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science 1986;234:47-52.
47. Shuai K. Interferon-activated signal transduction to the nucleus. Curr Opin Cell Biol 1994;6:253-9.
48. Fox CK, Furtwaengler A, Nepomuceno RR, et al. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001;21:272-9.